Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy

2026-03-13 - 12:36

SHANGHAI, March 13, 2026 /PRNewswire/ — On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This breakthrough marks UX-GIP001 as the first iPSC-derived allogeneic epilepsy cell therapy approved in the U.S. and